[
  {
    "ts": null,
    "headline": "Cardinal Health Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Cardinal Health Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3f03942e3a66741fb55f2a4f89c00af1cc456cb2a59d857f3fb03342cfaccf9b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733418180,
      "headline": "Cardinal Health Inc. stock underperforms Thursday when compared to competitors",
      "id": 131886755,
      "image": "",
      "related": "CAH",
      "source": "MarketWatch",
      "summary": "Cardinal Health Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3f03942e3a66741fb55f2a4f89c00af1cc456cb2a59d857f3fb03342cfaccf9b"
    }
  },
  {
    "ts": null,
    "headline": "PDCO Stock Gains Despite Q2 Earnings Miss and Lower Margins",
    "summary": "Patterson Companies' overall topline in the second quarter of fiscal 2025 benefits from strength in its Animal Health segment.",
    "url": "https://finnhub.io/api/news?id=3bbdb49356f02516c6857933fb7b9a18aea616b8735bb427489c9cf9ca817eb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733414820,
      "headline": "PDCO Stock Gains Despite Q2 Earnings Miss and Lower Margins",
      "id": 131796381,
      "image": "https://media.zenfs.com/en/zacks.com/32e3eb8c0cc46c163964cde251fb4426",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Patterson Companies' overall topline in the second quarter of fiscal 2025 benefits from strength in its Animal Health segment.",
      "url": "https://finnhub.io/api/news?id=3bbdb49356f02516c6857933fb7b9a18aea616b8735bb427489c9cf9ca817eb2"
    }
  },
  {
    "ts": null,
    "headline": "Strength Across Segments to Help CAH Stock Offset OptumRx Headwind?",
    "summary": "CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern.",
    "url": "https://finnhub.io/api/news?id=aadda49ea2d44eca03567d53214c5580b1ebe4c8992a521851324966882e7e94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733403000,
      "headline": "Strength Across Segments to Help CAH Stock Offset OptumRx Headwind?",
      "id": 131794901,
      "image": "https://media.zenfs.com/en/zacks.com/1d9b8c4d3a521aaa37ed9eaa516a47f0",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern.",
      "url": "https://finnhub.io/api/news?id=aadda49ea2d44eca03567d53214c5580b1ebe4c8992a521851324966882e7e94"
    }
  }
]